Bio: Quanjun Wang, Research Professor, Ph.D. Supervisor, CEO and Chief Scientist of Saifu laboratories; Ph.D. Supervisor in Biology and Pharmaceutical Engineering at the School of Pharmacy, East China Normal University. With over 20 years of experience in innovative drug research, he has led the successful IND approval of over 50 innovative drug candidates, including IL-12, and presided over 18 national and provincial-level projects, such as the National Major Scientific and Technological Project for "Significant New Drugs Development". He has filed more than 20 patents and published over 200 articles in prestigious journals (e.g., Nature Biomedical Engineering, CYTOTHERAPY, Experimental Hematology & Oncology, Frontiers in Immunology, Toxicology and Applied Pharmacology). He authored 2 monographs as the chief editor, including China’s first monograph Non-Clinical Evaluation Research on Cell and Gene Therapy Products, and co-authored 10 monographs. Professional Affiliations: Standing Director and Deputy Secretary-General of the Chinese Society of Toxicology; Chair of the Drug Toxicology and Safety Evaluation Committee, Chinese Society of Toxicology; Vice Chair of the Cell and Gene Therapy Drug Quality Research Committee, China Pharmaceutical Quality Management Association; Council Member of the Chinese Pharmaceutical Association; Council Member of the Radiopharmaceutical Branch, China Isotope and Radiation Association and so on.